Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MD1003 in progressive multiple sclerosis
2016-000700-29Phase 3Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing MD1003 300 mg/day with Placebo (2 arms). Primary endpoint: Clinical improvement in non-active progressive multiple sclerosis. Started Nov 2016; status: completed.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-000700-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000700-29.